Edilio Borroni Selected Research

(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanone

8/2018	Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.
6/2014	Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
2/2012	Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
6/2010	Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edilio Borroni Research Topics

Disease

9	Schizophrenia (Dementia Praecox) 08/2018 - 08/2002
8	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2017
6	Parkinson Disease (Parkinson's Disease) 02/2015 - 11/2002
5	Dementia (Dementias) 01/2022 - 09/2007
4	Cognitive Dysfunction 01/2022 - 09/2007
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 09/2007
3	Mental Disorders (Mental Disorder) 08/2018 - 09/2014
2	Fragile X Syndrome (Martin Bell Syndrome) 04/2015 - 02/2015
1	Prodromal Symptoms 01/2021
1	Primary Progressive Aphasia 01/2020
1	beta-Thalassemia (Cooley's Anemia) 08/2018
1	Amyloid Plaque 01/2017
1	Gliosis 01/2017
1	Serotonin Syndrome (Syndrome, Serotonin) 01/2017
1	Nervous System Diseases (Neurological Disorders) 01/2017
1	Lethargy 04/2015
1	Pain (Aches) 04/2015
1	Disorders of Excessive Somnolence (Hypersomnia) 04/2015
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 02/2015
1	Dyskinesias (Dyskinesia) 02/2015
1	Narcolepsy 03/2011
1	Cataplexy 03/2011
1	Sleepiness 03/2011
1	Heart Diseases (Heart Disease) 05/2005
1	Synucleinopathies 11/2002
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2002

Drug/Important Bio-Agent (IBA)

5	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2018
5	Pharmaceutical PreparationsIBA 08/2018 - 01/2002
5	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2016 - 08/2002
4	Glycine (Aminoacetic Acid)FDA LinkGeneric 08/2018 - 12/2003
4	(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanoneIBA 08/2018 - 06/2010
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2017
3	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2021 - 01/2020
3	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 05/2011 - 01/2003
3	EnzymesIBA 05/2011 - 01/2003
2	Monoamine Oxidase (MAO)IBA 01/2017 - 01/2017
2	Antidepressive Agents (Antidepressants)IBA 01/2017 - 04/2015
2	sembragilineIBA 01/2017 - 01/2017
2	N-Methylaspartate (NMDA)IBA 04/2016 - 02/2012
2	Neurotransmitter Agents (Neurotransmitter)IBA 11/2015 - 03/2006
2	2- chloro- 4- (1- (4- fluorophenyl)- 2,5- dimethyl- 1H- imidazol- 4- ylethynyl)pyridineIBA 04/2015 - 02/2015
2	pyridineIBA 04/2015 - 02/2015
2	Levodopa (L Dopa)FDA LinkGeneric 02/2015 - 05/2011
2	Glutamic Acid (Glutamate)FDA Link 09/2014 - 07/2009
2	alpha-SynucleinIBA 09/2007 - 11/2002
1	Apolipoproteins E (ApoE)IBA 01/2021
1	FluorineIBA 01/2021
1	Memantine (Namenda)FDA Link 01/2017
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2017
1	Fluoxetine (Prozac)FDA LinkGeneric 01/2017
1	Amyloid beta-PeptidesIBA 01/2017
1	Serotonin (5 Hydroxytryptamine)IBA 01/2017
1	TyramineIBA 01/2017
1	Dopamine (Intropin)FDA LinkGeneric 11/2015
1	Metabotropic Glutamate 5 ReceptorIBA 02/2015
1	antineoplaston A10 (A 10)IBA 02/2015
1	Diazepam (Valium)FDA LinkGeneric 02/2015
1	gamma-Aminobutyric Acid (GABA)IBA 09/2014
1	Antipsychotic Agents (Antipsychotics)IBA 06/2014
1	Cre recombinaseIBA 03/2011
1	OrexinsIBA 03/2011
1	Orexin ReceptorsIBA 03/2011
1	CatecholaminesIBA 03/2006
1	Protein Isoforms (Isoforms)IBA 05/2005
1	Cyclophilins (Cyclophilin)IBA 05/2005
1	Glycine Plasma Membrane Transport ProteinsIBA 12/2003
1	Endopeptidase K (Proteinase K)IBA 11/2002
1	Tolcapone (Tasmar)FDA Link 01/2002

Therapy/Procedure

2	Therapeutics 01/2017 - 12/2003